drugset / Trial / NCT01639885
Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer
Phase 1/2
Completed
15 enrolled
Leiden University Medical Center
University Medical Center Groningen · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study investigates the feasibility and immunogenicity of the triple combination of gemcitabine, Peg-Intron and p53 SLP vaccination in patients with platinum-resistant ovarian cancer.
Timeline
- Start
- 2011-08
- Primary completion
- 2014-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interferon alfa-2b | Protein / enzyme biologic | 1 ug/kg | — |
| Subject | p53 SLP | Vaccine | 0.3 mg | Subcutaneous |